Calcium L-Threonate
(Synonyms: L-苏糖酸钙) 目录号 : GC62884
L-Threonic acid Calcium Salt (Calcium threonate) is a calcium salt of threnoic acid. L-Threonic acid is a metabolite of ascorbic acid (vitamin C).
Cas No.:70753-61-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
L-Threonic acid Calcium Salt (Calcium threonate) is a calcium salt of threnoic acid. L-Threonic acid is a metabolite of ascorbic acid (vitamin C).
| Cas No. | 70753-61-6 | SDF | |
| 别名 | L-苏糖酸钙 | ||
| 分子式 | C4H7CaO5+ | 分子量 | 175.17 |
| 溶解度 | Water : 5 mg/mL (28.54 mM; ultrasonic and warming and heat to 60°C) | 储存条件 | 4°C, away from moisture |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.7087 mL | 28.5437 mL | 57.0874 mL |
| 5 mM | 1.1417 mL | 5.7087 mL | 11.4175 mL |
| 10 mM | 0.5709 mL | 2.8544 mL | 5.7087 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Calcium bioavailability of Calcium L-Threonate in healthy Chinese subjects measured with stable isotopes (⁴⁴Ca and ⁴²Ca)
Eur J Clin Pharmacol 2013 May;69(5):1121-6.PMID:23229796DOI:10.1007/s00228-012-1420-5.
Purpose: Calcium L-Threonate is a novel drug that was developed for the treatment of osteoporosis and as a calcium supplement. However, calcium bioavailability of this drug is unknown due to lack of effective evaluation methods. In this study, we sought to measure the bioavailability of Calcium L-Threonate with a double-label stable isotope method. Methods: Fourteen healthy Chinese subjects were enrolled in the clinical study and were given 300 mg Calcium L-Threonate tablets containing 40 mg (44)Ca after an intravenous injection of 4 mg (42)Ca solution (as calcium chloride). Fractional urine samples were collected at the following time intervals: 0-3, 3-6, 6-9, 9-13, 13-24, 24-36 and 36-48 h. The abundance ratios of (44)Ca/(40)Ca and (42)Ca/(40)Ca in the urine were determined with thermal-ionization mass spectrometry (TI-MS). The calcium bioavailability was estimated by calculating the true fractional calcium absorption (TFCA) using the abundance ratios of (44)Ca/(40)Ca and (42)Ca/(40)Ca. Results: The bioavailability of Calcium L-Threonate in 14 healthy Chinese subjects was 26.49 ± 9.39 %. There was good agreement between TFCA from the 24 to 36 h and the 36 to 48 h urine pool, indicating that calcium balance was achieved at 24 h after dosing. The TFCA of the subjects did not statistically correlate with total urinary calcium excretion (0-48 h). There were no serious adverse events in this study. Conclusions: The bioavailability of Calcium L-Threonate in humans was successfully determined by estimating TFCA with the double-label stable isotope method, thus providing a useful approach for the evaluation of bioavailability of calcium formulations.
Pharmacokinetics and safety of Calcium L-Threonate in healthy volunteers after single and multiple oral administrations
Acta Pharmacol Sin 2011 Dec;32(12):1555-60.PMID:21986570DOI:10.1038/aps.2011.138.
Aim: To evaluate the pharmacokinetics of L-threonate after single or multiple oral administrations and its safety profile in healthy Chinese volunteers. Methods: This was an open-label, single- and multiple-dose study. The subjects were assigned to receive a single dose, 675, 2025, or 4050 mg, of Calcium L-Threonate (n=12) or repeated doses of 2025 mg twice daily for 4 d (n=12). Serial plasma and urine samples were analyzed with HPLC-MS/MS. Pharmacokinetic parameters of L-threonate were calculated using non-compartmental analysis with WinNonlin software. Results: In the single dose group, C(max) reached at 2.0 h and the mean t(1/2) was approximately 2.5 h. Area under curve (AUC) and C(max) increased with dose escalation, but dose proportionality was not observed over the range of 675 to 4050 mg. AUC and C(max) in the fasted subjects were lower compared with those in the non-fasted subjects. Cumulative urinary excretion of L-threonate over 24 h represented 5.9% of the administered dose with a mean Cl/r of 0.8 L/h. In the multiple-dose study, no accumulation appeared upon repeated doses of 2025 mg twice daily for 4 d. There were no serious adverse events that occurred during this study. Conclusion: Calcium L-Threonate was well tolerated in healthy Chinese subjects, with no pattern of dose-related adverse events. Plasma exposure increased with dose escalation, but linear pharmacokinetics were not observed over the studied doses. L-threonate was absorbed rapidly, and its absorption was enhanced by food intake. No systemic accumulation appeared after repeated administrations.
Stimulatory action of Calcium L-Threonate on ascorbic acid uptake by a human T-lymphoma cell line
Life Sci 1991;49(19):1377-81.PMID:1943443DOI:10.1016/0024-3205(91)90388-r.
The effects of preincubation of human T-lymphoma cells with increasing concentrations of Calcium L-Threonate on the uptake of L-[1-14C]ascorbic acid were examined. Calcium L-Threonate (0-1,000 mg%) stimulated ascorbic acid (1.25 mg%) uptake in a dose-dependent manner. These results indicate that calcium threonate and possibly other ascorbic acid metabolites have biological activity and potential pharmacological applications.
Determination of L-threonate in Calcium L-Threonate preparations by capillary electrophoresis with indirect UV detection
Electrophoresis 1999 Jul;20(9):1850-5.PMID:10445326DOI:10.1002/(SICI)1522-2683(19990701)20:9<1850::AID-ELPS1850>3.0.CO;2-M.
A validated capillary electrophoresis method with indirect UV detection for the determination of L-threonate in a Calcium L-Threonate (Ca-Th) chewable tablet and dry syrup was described. The 2,6-naphthalenedicarboxylic acid (NDC) was used as the background carrier ion and the tetradecyltrimethylammonium bromide (TTAB) was used as electroosmotic flow modifier. The running buffer contained 2 mM NDC, 6 mM disodium carbonate and 0.2 mM TTAB. The detection wavelength was set at 240 nm. A linear calibration range of 50-500 microg/mL was obtained (r = 0.9996). The limit of detection and limit of quantitation were found to be 6 microg/mL and 20 microg/mL, respectively. The recovery was 99.45% (RSD = 0.57%, n = 5) and 99.12% (RSD = 0.48%, n = 5) for the tablet and dry syrup preparation, respectively. Repeatability tests on the migration times or peak areas proved that the results were of high precision. The RSD of peak area ratio was lower than 1% (0.74%, n = 5). The factors influencing quantitation were discussed and three batches of chewable tablet and also of dry syrup were assayed by the proposed method.
[Effects of L-threonate on bone resorption by osteoclasts in vitro]
Sichuan Da Xue Xue Bao Yi Xue Ban 2005 Mar;36(2):225-8.PMID:15807273doi
Objective: To clarify if Calcium L-Threonate and sodium L-threonate have inhibitory effects on the bone resorption of rabbit's osteoclasts in vitro. Methods: This study contained a total of 16 culture groups, including one group as control and 5 groups treated by 5 drugs (calcium D-threonate, sodium L-threonate, alendronate, 17beta-estradiol and calcium gluconate) each at the final concentrations of 10(-9) mol/L, 10(-7) mol/L, 10(-5) mol/L respectively. After 7 days, eight bone slices of every group were stained with toluidine blue and the areas of resorptive pits were analyzed under light microscope; the concentrations of C-telopeptide of type I collagen (CTx or Crosslaps) in culture supernatants were measured by ELISA. Results: (1) The resorption area and the CTx concentration of the Calcium L-Threonate groups were reduced significantly as compared with those of control and of Calcium gluconate groups respectively. The resorption area and CTx level of the Sodium L-threonate groups were significantly reduced when compared with those of the control, but the effects of Calcium gluconate groups were not so. (2) The reduction in the resorption area and CTx concentration of Calcium L-Threonate group was more than that of Sodium L-threonate group. (3) The reductive effect of the high concentration (10(-5)) group of Calcium L-Threonate on the area and CTx level was corresponding to that of 17beta-estradiol at a concentration between 10(-7) and 10(-9). (4) The resorption area was related to the CTx concentration (r=0.876). (5) The CTX level was much more sensitive, precise and stable than the concentration. Conclusion: L-threonate, especially Calcium L-Threonate could inhibit the bone resorption of osteoclasts in vitro, and its effect might be related to the radical of L-threonic acid. The CTx concentration in culture supernatants might be an effective marker quantitatively reflecting the bone resorption by osteoclasts in vitro.